ibutilide / Generic mfg. - LARVOL DELTA

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) - P4 | N=27 | Completed | Sponsor: Indiana University | N=16 ➔ 27

Enrollment change • Cardiovascular

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) - P4 | N=73 | Completed | Sponsor: Indiana University | Active, not recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Apr 2025

Trial completion • Trial completion date

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) - P4 | N=83 | Active, not recruiting | Sponsor: Indiana University | Trial primary completion date: Oct 2025 ➔ Apr 2025

Trial primary completion date

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) - P4 | N=83 | Active, not recruiting | Sponsor: Indiana University | Recruiting ➔ Active, not recruiting

Enrollment closed

A SHORT-SHORT CIRCUIT — A CASE OF ATYPICAL AVNRT WITH A LOWER COMMON PATHWAY BLOCK - Hamid Shirwany (ACC 2025) - "Afterwards, she required inotropes for cardiogenic shock and developed recurrent SVT resistant to adenosine, amiodarone, and ibutilide.Decision-making: Repeat EPS demonstrated inducible SVT following AH jump with Wenckebach conduction of the AH interval and droped His without a change in the TCL. This case highlights a rare presentation of AVNRT and the importance of recognizing tachycardia-medicated cardiomyopathy."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Ventricular Tachycardia

Effect of the Membrane Environment on Pharmacologic Inhibition of hERG K+ Channel Activity. (PubMed, JACC Clin Electrophysiol) - "These results support the idea that the lipid environment of the plasma membrane plays a role in the ability of certain drugs to inhibit hERG channel activity. Differences in membrane cholesterol content may affect the ability of some hERG channel blockers to produce arrhythmogenic behavior."

Journal • Cardiovascular • Ventricular Tachycardia

Clinical Efficacy and Safety of Ibutilide in Cardioversion of Atrial Fibrillation or Flutter in Indian Patients: A Multicenter Study. (PubMed, Indian J Crit Care Med) - "Dewan B, Navale S, Shinde S, Chaudhary J. Clinical Efficacy and Safety of Ibutilide in Cardioversion of Atrial Fibrillation or Flutter in Indian Patients: A Multicenter Study. Indian J Crit Care Med 2025;29(1):45-51."

Clinical • Journal • Atrial Fibrillation • Cardiovascular • Pain • Ventricular Tachycardia

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) - P4 | N=83 | Recruiting | Sponsor: Indiana University | Trial completion date: Dec 2024 ➔ Oct 2025 | Trial primary completion date: Dec 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date

Chemical Cardioversion of Atrial Arrhythmias with Ibutilide in Children and Adults with Congenital Heart Disease. (PubMed, Pediatr Cardiol) - "Presentation in atrial flutter (P = 0.08) and male gender (0.07) showed a trend towards significance. Adverse effects were reported after 8 ibutilide administrations (7.6%, n = 6/8 [75%] female)."

Journal • Cardiovascular • Heart Failure • Pediatrics • Ventricular Tachycardia

Mechanisms of Chemical Atrial Defibrillation by Flecainide and Ibutilide. (PubMed, JACC Clin Electrophysiol) - "We predict the drug concentrations that promote efficacy of flecainide and ibutilide used in combination for atrial chemical defibrillation. We also predict the potential safety pharmacology impact of this drug combination on ventricular electrophysiology."

Journal • Cardiovascular

Drug-induced increase in dispersion of ventricular repolarization in patients with heart failure with preserved ejection fraction. (PubMed, Int J Cardiol) - "HFpEF is associated with enhanced response to drug-induced increases in dispersion of repolarization."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review. (PubMed, Clin Cardiol) - "Antiarrhythmics are not uniformly affected by obesity. This observation is based on heterogeneous studies of participants with an average BMI and poorly controlled confounding factors such as multimorbidity, concomitant medications, varying routes of administration, and assessment of obesity. Controlled trials with stratification at the time of recruitment for obesity are necessary to determine the significance of these findings."

Journal • Review • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Obesity

External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "Despite the low quality of evidence, this systematic review provides important information on electrical and pharmacological strategies to help patients and physicians deal with AF and atrial flutter. In the assessment of the patient comorbidity profile, antiarrhythmic drug onset of action and side effect profile versus the need for a physician with experience in sedation, or anaesthetics support for electrical cardioversion are key aspects when choosing the cardioversion method."

Clinical • Journal • Retrospective data • Review • Anesthesia • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) - P4 | N=16 | Completed | Sponsor: Indiana University | Active, not recruiting ➔ Completed

Trial completion

WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATION IN AN OTHERWISE HEALTHY YOUNG MALE (ACC 2024) - "The patient was instead given 1 mg Ibutilide and 500 mg Procainamide... Prompt recognition of the WPW and AF via ECG is important in the proper treatment of this arrhythmia (usually with class IA, IC, or III antiarrhythmics) to prevent degeneration to VF. We share this case to raise awareness of the detrimental effects of misdiagnosis and mistreatment of a rare yet serious condition."

Clinical • Atrial Fibrillation • Cardiovascular • CNS Disorders • Movement Disorders

ENHANCED RESPONSE TO DRUG-INDUCED LENGTHENING OF LATE VENTRICULAR REPOLARIZATION AND INCREASED TRANSMURAL DISPERSION OF REPOLARIZATION IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (ACC 2024) - "HFpEF is associated with enhanced response to drug-induced increases in TDR and lengthening of late ventricular repolarization."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) - P4 | N=16 | Active, not recruiting | Sponsor: Indiana University | Recruiting ➔ Active, not recruiting | N=40 ➔ 16

Enrollment change • Enrollment closed

Analysis of the success rate of conversion using ibutilide administration in radiofrequency catheter ablation of persistent atrial fibrillation and its effects on postoperative recurrence. (PubMed, BMC Cardiovasc Disord) - "Ibutilide showed to be effective in catheter ablation of AF, the success rate of conversion was correlated with the duration of AF, LA diameter, and NT-proBNP level. Besides, the duration of AF was found as a risk factor for early postoperative recurrence, while ibutilide administration for successful conversion had no influence on predicting postoperative recurrence and had no influence on postoperative maintenance time of sinus rhythm."

Journal • Atrial Fibrillation • Cardiovascular • NPPB

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Indiana University | Trial completion date: Feb 2024 ➔ Jul 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date

Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis. (PubMed, Cardiovasc Drugs Ther) - "Among guideline-recommended antidysrhythmic drugs, the combination of digoxin IV and amiodarone IV is definitely among the least safe for cardioversion of recent onset AF; flecainide, vernakalant, ibutilide, propafenone, and amiodarone IV are definitely among the most effective for cardioversion within 4 h; flecainide is definitely among the most effective for cardioversion within 24 h. Further, randomized controlled trials with predetermined and strictly defined, hemodynamic adverse event outcomes are recommended."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Hypotension

Treatment of atrial fibrillation. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular

Gender Differences With Ibutilide Effectiveness and Safety in Cardioversion of Atrial Fibrillation. (PubMed, J Surg Res) - "Within our population, pretreatment with magnesium sulfate followed by ibutilide was associated with increased conversion to NSR. Additionally, we noted that females had a higher conversion rate to NSR compared to males, regardless of whether they were pretreated with magnesium sulfate."

Journal • Atrial Fibrillation • Cardiovascular • Critical care

Effect of Flecainide and Ibutilide Alone and in Combination to Terminate and Prevent Recurrence of Atrial Fibrillation. (PubMed, Circ Arrhythm Electrophysiol) - "Torsades de Pointes score was relatively high with ibutilide alone and low with the drug combination. In our experimental model, a combination of flecainide and ibutilide significantly improves cardioversion and prevents the recurrence of AF compared with monotherapies with little to no risk for the development of long-QT-mediated ventricular proarrhythmia."

Journal • Atrial Fibrillation • Cardiovascular

Comparison of clinical outcomes of Ibutilide-guided cardioversion and direct current synchronized cardioversion after radiofrequency ablation of persistent atrial fibrillation. (PubMed, Front Cardiovasc Med) - "Furthermore, subgroup analysis showed that freedom from ATT rate in effective Ibutilide subgroup was significantly higher than noneffective Ibutilide subgroup (Log-rank, P < 0.001). For the treatment of the patients with PsAF, Ibutilide-guided cardioversion after individualized RFCA may be benefit for maintenance of SR compared to conventional DCC, especially for the patients who are effective for administration of Ibutilide."

Clinical data • Journal • Atrial Fibrillation • Cardiovascular

Evaluation of the Safe Use of Ibutilide in a Multicenter Health System (ASHP 2023) - No abstract available

Clinical • Cardiovascular